These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 15867496)

  • 21. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries.
    ; Zwahlen M; Harris R; May M; Hogg R; Costagliola D; de Wolf F; Gill J; Fätkenheuer G; Lewden C; Saag M; Staszewski S; d'Arminio Monforte A; Casabona J; Lampe F; Justice A; von Wyl V; Egger M
    Int J Epidemiol; 2009 Dec; 38(6):1624-33. PubMed ID: 19820106
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study.
    Etard JF; Ndiaye I; Thierry-Mieg M; Guèye NF; Guèye PM; Lanièce I; Dieng AB; Diouf A; Laurent C; Mboup S; Sow PS; Delaporte E
    AIDS; 2006 May; 20(8):1181-9. PubMed ID: 16691070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort.
    Saracino A; Lorenzini P; Lo Caputo S; Girardi E; Castelli F; Bonfanti P; Rusconi S; Caramello P; Abrescia N; Mussini C; Monno L; d'Arminio Monforte A;
    Clin Microbiol Infect; 2016 Mar; 22(3):288.e1-8. PubMed ID: 26551839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved outcomes of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral therapy.
    Hung CC; Chen MY; Hsiao CF; Hsieh SM; Sheng WH; Chang SC
    AIDS; 2003 Dec; 17(18):2615-22. PubMed ID: 14685055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
    Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
    Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine.
    Mocroft A; Devereux H; Kinloch-de-Loes S; Wilson D; Madge S; Youle M; Tyrer M; Loveday C; Phillips AN; Johnson MA
    AIDS; 2000 Jul; 14(11):1545-52. PubMed ID: 10983641
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regional differences in the risk of triple class failure in European patients starting combination antiretroviral therapy after 1 January 1999.
    Mocroft A; Horban A; Clotet B; d'Arminio Monforte A; Bogner JR; Aldins P; Staub T; Antunes F; Katlama C; Lundgren JD;
    HIV Med; 2008 Jan; 9(1):41-6. PubMed ID: 18199171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts.
    Mocroft A; Staszewski S; Weber R; Gatell J; Rockstroh J; Gasiorowski J; Panos G; Monforte Ad; Rakhmanova A; Phillips AN; Lundgren JD;
    Antivir Ther; 2007; 12(3):325-33. PubMed ID: 17591022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The incidence rate of HIV type-1 drug resistance in patients on antiretroviral therapy: a nationwide population-based Danish cohort study 1999-2005.
    Audelin AM; Lohse N; Obel N; Gerstoft J; Jørgensen LB
    Antivir Ther; 2009; 14(7):995-1000. PubMed ID: 19918103
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Survival status and influencing factors of HIV/AIDS on highly active anti-retrovial therapy in Shandong province].
    Zhang N; Zhu XY; Wang GY; Tao XR; Wang N; Kang DM
    Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Jan; 40(1):74-78. PubMed ID: 30669735
    [No Abstract]   [Full Text] [Related]  

  • 31. Increased risk of early virological failure in non-European HIV-1-infected patients in a Dutch cohort on highly active antiretroviral therapy.
    van den Berg JB; Hak E; Vervoort SC; Hoepelman IM; Boucher CA; Schuurman R; Schneider MM
    HIV Med; 2005 Sep; 6(5):299-306. PubMed ID: 16156876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
    Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
    Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of cataract surgery in HIV-infected individuals: a Danish Nationwide Population-based cohort study.
    Rasmussen LD; Kessel L; Molander LD; Pedersen C; Gerstoft J; Kronborg G; Obel N
    Clin Infect Dis; 2011 Dec; 53(11):1156-63. PubMed ID: 21998282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.
    Ledergerber B; Egger M; Erard V; Weber R; Hirschel B; Furrer H; Battegay M; Vernazza P; Bernasconi E; Opravil M; Kaufmann D; Sudre P; Francioli P; Telenti A
    JAMA; 1999 Dec; 282(23):2220-6. PubMed ID: 10605973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study.
    Mussini C; Lorenzini P; Cozzi-Lepri A; Lapadula G; Marchetti G; Nicastri E; Cingolani A; Lichtner M; Antinori A; Gori A; d'Arminio Monforte A;
    Lancet HIV; 2015 Mar; 2(3):e98-106. PubMed ID: 26424550
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain.
    Rodríguez-Arenas MA; Jarrín I; del Amo J; Iribarren JA; Moreno S; Viciana P; Peña A; Sirvent JL; Vidal F; Lacruz J; Gutierrez F; Oteo JA; Asencio R; Castilla J; Hoyos SP;
    AIDS Res Hum Retroviruses; 2006 Aug; 22(8):715-23. PubMed ID: 16910826
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment Failure in HIV-Infected Children on Second-line Protease Inhibitor-Based Antiretroviral Therapy.
    Suaysod R; Ngo-Giang-Huong N; Salvadori N; Cressey TR; Kanjanavanit S; Techakunakorn P; Krikajornkitti S; Srirojana S; Laomanit L; Chalermpantmetagul S; Lallemant M; Le Cœur S; McIntosh K; Traisathit P; Jourdain G
    Clin Infect Dis; 2015 Jul; 61(1):95-101. PubMed ID: 25838288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of triple-class virological failure in children with HIV: a retrospective cohort study.
    ; Castro H; Judd A; Gibb DM; Butler K; Lodwick RK; van Sighem A; Ramos JT; Warsawski J; Thorne C; Noguera-Julian A; Obel N; Costagliola D; Tookey PA; Colin C; Kjaer J; Grarup J; Chene G; Phillips A
    Lancet; 2011 May; 377(9777):1580-7. PubMed ID: 21511330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.